Plaquenil and Arava Weight Effects
Neither Plaquenil (hydroxychloroquine) nor Arava (leflunomide) are associated with clinically significant weight gain based on available evidence.
Direct Evidence Assessment
The provided evidence does not contain any guidelines, drug labels, or research studies specifically addressing weight changes with Plaquenil (hydroxychloroquine) or Arava (leflunomide). The evidence focuses primarily on:
- Antiretroviral medications for HIV 1
- Diabetes medications 2
- Antidepressants 3, 4, 5
- Antipsychotics 6, 7
- Various other drug classes 8, 9, 10
Clinical Context from General Medicine Knowledge
Plaquenil (hydroxychloroquine):
- This antimalarial/disease-modifying antirheumatic drug (DMARD) is not recognized as causing weight gain
- Weight changes are not listed among common or significant adverse effects
- Gastrointestinal side effects (nausea, diarrhea) may occasionally lead to weight loss rather than gain
Arava (leflunomide):
- This DMARD used for rheumatoid arthritis is not associated with weight gain
- Common side effects include diarrhea, nausea, and elevated liver enzymes
- Gastrointestinal effects may potentially cause weight loss in some patients
Medications That DO Cause Weight Gain
For context, the evidence clearly identifies medications associated with significant weight gain 9:
Antidepressants causing weight gain:
Antipsychotics causing weight gain:
Antidiabetic medications causing weight gain:
Clinical Recommendation
If your patient is experiencing weight gain while taking Plaquenil and/or Arava, investigate other causes rather than attributing it to these medications. Consider:
- Other concurrent medications (antidepressants, antipsychotics, diabetes medications, corticosteroids) 8, 9, 10
- Disease activity changes (improved mobility leading to different activity patterns)
- Corticosteroid use (commonly co-prescribed with DMARDs)
- Metabolic or endocrine disorders
- Dietary and lifestyle factors